688363 華熙生物
按盤價 
44.180 +0.560 (+1.284%) | 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 3,163,399 | -18.36% | 5,370,770 | 6,075,924 | 6,359,192 | 4,947,774 | |
| 減：營業總成本 | 2,850,484 | -16.63% | 5,039,860 | 5,438,234 | 5,322,193 | 4,165,938 | |
| 其中:營業成本 | 927,355 | -8.20% | 1,392,562 | 1,621,028 | 1,463,227 | 1,085,252 | |
| 財務費用 | (12,676) | 77.64% | (6,955) | (30,795) | (48,657) | (495) | |
| 資產減值損失 | (47,104) | 159.47% | (159,086) | (54,403) | (15,447) | (29,828) | |
| 公允價值變動收益 | 850 | 2,546.28% | 1,415 | 1,468 | (143) | 7,394 | |
| 投資收益 | (9,001) | 80.16% | (12,536) | 1,327 | 11,915 | 20,646 | |
| 其中：對聯營企業和合營企業的投資收益 | (9,469) | 54.30% | (13,849) | (1,652) | (2,360) | (344) | |
| 營業利潤 | 291,698 | -33.12% | 215,940 | 708,386 | 1,136,314 | 905,553 | |
| 利潤總額 | 291,533 | -33.22% | 213,393 | 701,722 | 1,136,112 | 890,199 | |
| 減：所得稅費用 | 39,210 | -49.42% | 44,987 | 118,980 | 174,732 | 114,643 | |
| 淨利潤 | 252,323 | -29.72% | 168,406 | 582,742 | 961,380 | 775,556 | |
| 減：非控股權益 | (57) | -98.07% | (5,861) | (9,814) | (9,538) | (6,779) | |
| 股東淨利潤 | 252,380 | -30.29% | 174,267 | 592,556 | 970,919 | 782,335 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.520 | -30.67% | 0.360 | 1.230 | 2.020 | 1.630 | |
| 每股派息 (元) * | -- | -- | 0.110 | 0.380 | 0.610 | 0.490 | |
| 每股淨資產 (元) * | 14.657 | 0.58% | 14.138 | 14.416 | 13.789 | 11.873 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 19/12/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
